CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
4.2770
4.68%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.1860
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024346 %
Charges from full value of position ($-4.63)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002124 %
Charges from full value of position ($0.40)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 4.487
Open 4.347
1-Year Change 738.7%
Day's Range 4.097 - 4.347
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 17, 2024 4.4870 0.0600 1.36% 4.4270 4.5470 4.2670
Dec 16, 2024 4.5570 -0.0200 -0.44% 4.5770 4.6470 4.3870
Dec 13, 2024 4.6370 -0.1100 -2.32% 4.7470 4.7470 4.5470
Dec 12, 2024 4.6470 0.0600 1.31% 4.5870 4.9470 4.3770
Dec 11, 2024 4.9370 0.0400 0.82% 4.8970 5.1170 4.7370
Dec 10, 2024 4.8870 -0.2500 -4.87% 5.1370 5.1570 4.8870
Dec 9, 2024 4.9570 0.1500 3.12% 4.8070 5.3770 4.6970
Dec 6, 2024 4.7070 -0.1300 -2.69% 4.8370 4.9670 4.5470
Dec 5, 2024 4.8170 -0.1200 -2.43% 4.9370 5.1170 4.7870
Dec 4, 2024 4.7270 0.0200 0.42% 4.7070 5.1270 4.4770
Dec 3, 2024 5.0270 -0.0900 -1.76% 5.1170 5.3170 4.8870
Dec 2, 2024 5.2070 0.2100 4.20% 4.9970 5.4070 4.7570
Nov 29, 2024 5.1270 -0.3900 -7.07% 5.5170 5.5170 4.8870
Nov 27, 2024 4.9970 -0.2400 -4.58% 5.2370 5.5470 4.7070
Nov 26, 2024 5.1470 -0.0900 -1.72% 5.2370 5.2970 4.6470
Nov 25, 2024 5.1870 0.1500 2.98% 5.0370 5.3970 4.9470
Nov 22, 2024 4.4170 -0.1900 -4.12% 4.6070 4.7270 4.4170
Nov 21, 2024 4.5870 -0.3200 -6.52% 4.9070 4.9070 4.4870
Nov 20, 2024 4.8570 -0.0100 -0.21% 4.8670 5.1070 4.6670
Nov 19, 2024 4.9470 0.0000 0.00% 4.9470 5.0370 4.4370

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Pluri Inc. Company profile

About Pluristem Therapeutics Inc.

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

Financial summary

BRIEF: For the six months ended 31 December 2021, Pluristem Therapeutics Inc. revenues was not reported. Net loss increased 6% to $22.4M. Higher net loss reflects General and administrative expenses increase of 30% to $4.8M (expense), Stock-based Compensation in SGA increase of 9% to $4.6M (expense), Research & Development Expense decrease of 75% to $72K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.82 to -$0.70.

Equity composition

Common Stock $0.00001 Par, 01/13, 100M auth., 58,333,206 issd. Insiders control 11.74%. IPO: NA. 11/07,1-for-200 reverse stock split. 11/07, Name changed from Pluristem Life Systems, Inc. 12/07, Exchanged changed from OTC Bulletin Board to NASDAQ.

Industry: Biotechnology & Medical Research (NEC)

Matam Park Building 5
HAIFA
3508409
IL

People also watch

ETH/USD

3,869.41 Price
-1.670% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

BTC/USD

104,210.30 Price
-2.280% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Gold

2,636.12 Price
-0.410% 1D Chg, %
Long position overnight fee -0.0083%
Short position overnight fee 0.0001%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

21,988.50 Price
+0.050% 1D Chg, %
Long position overnight fee -0.0243%
Short position overnight fee 0.0021%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading